Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Gastroenterology · LACC1-Associated Juvenile Arthritis

Living with the Long-Term Outlook

At a Glance

LACC1-associated juvenile arthritis is a lifelong condition that can damage joints, so care focuses on controlling inflammation, preserving movement, monitoring growth and possible complications, and helping children gradually manage their own care.

Living with LACC1-associated juvenile arthritis is often described as a marathon rather than a sprint. Because this is a life-long genetic condition, the focus shifts from just “treating a flare” to managing your child’s long-term health and preventing permanent damage. While the disease can be aggressive, knowing what to monitor allows you and your care team to stay one step ahead [1][2].

Protecting Joint Health

The most significant long-term risk in LACC1-associated arthritis is progressive erosive arthritis. In historical cohorts, high percentages of children developed permanent wear-and-tear on their bones and cartilage, often despite being on strong medications [2].

  • Imaging Surveillance: There is no single universal imaging schedule for LACC1 disease. Frequency and modality (like X-rays or MRIs) should depend on the clinical examination, symptoms, prior damage, and whether imaging will change management. The emphasis is on clinical and functional monitoring [3][4].
  • The Role of Rehabilitation: Physical and occupational therapy are not optional “extras”—they are core treatments [1]. These specialists help your child maintain a full range of motion, build muscle strength, manage fatigue, and secure school accommodations [5].

Monitoring Extra-Articular Complications

“Extra-articular” means symptoms that occur outside the joints. While some complications have been observed, they are not universally expected.

The Gut (Crohn’s Disease)

There are known statistical associations between common LACC1 variants and Crohn’s disease, a type of inflammatory bowel disease (IBD) [6][7]. However, this does not establish Crohn’s as a routine expected complication.

  • Watch For: Chronic abdominal symptoms, diarrhea, blood in stool, anemia, or poor growth [8].
  • Screening Tool: Routine screening in asymptomatic children is not standard. If clinical concerns arise, doctors may use a symptom-triggered stool test called fecal calprotectin and refer to gastroenterology [9].

The Kidneys (Renal Amyloidosis)

Renal amyloidosis is a recognized, theoretical complication of prolonged, poorly controlled systemic inflammation [10]. It is not a documented LACC1-specific expectation.

  • Screening Tool: Any urinalysis, serum amyloid A, or renal-function screening schedule should be individualized by the treating team based on the child’s inflammatory burden [11][10].

Growth and Nutrition

Persistent inflammation and long-term steroid use can both interfere with a child’s natural growth [8][12]. Your team should plot your child’s height and weight on growth charts at every visit. A pediatric dietitian can be helpful if your child is struggling to gain weight or has a poor appetite due to their medications [8].

Supporting the Whole Family

The emotional toll of raising a child with a severe, early-onset disease is substantial. It is normal for parents to experience caregiver burnout, and siblings may also feel the stress of a brother or sister being frequently ill [13].

  • Sleep and Wellness: Studies in similar autoinflammatory diseases show that sleep quality for both the child and the parent is a major predictor of how well the family copes [14].
  • Transition Planning: As your child grows into their teenage years, their care team will begin a process called transitioning, which slowly teaches the young adult how to manage their own medications and appointments [15]. This process is readiness-based rather than tied to fixed ages [15][16].

Remember that while the historical statistics on joint damage reflect early cohorts, careful monitoring and individualized care offer hope for better disease control. By maintaining a strong support system and working closely with your care team, you are giving your child the best possible chance at a vibrant life.

Common questions in this guide

What is the long-term outlook for a child with LACC1-associated juvenile arthritis?
LACC1-associated juvenile arthritis is lifelong and can be aggressive, with a risk of progressive joint damage. The outlook varies between children, and ongoing monitoring, individualized treatment, and rehabilitation may help improve disease control and preserve function.
How is joint damage monitored in LACC1-associated juvenile arthritis?
Doctors use physical examinations and functional assessments to monitor joint health. X-rays or MRI scans may be recommended when symptoms, examination findings, previous damage, or a likely change in treatment makes imaging useful; there is no single schedule for every child.
Does LACC1-associated juvenile arthritis mean my child will develop Crohn’s disease?
No. Some common LACC1 variants are statistically associated with Crohn’s disease, but Crohn’s disease is not a routine expected complication of LACC1-associated arthritis. Persistent abdominal pain, diarrhea, blood in the stool, anemia, or poor growth should be discussed with the care team and may lead to stool testing or a gastroenterology referral.
How are kidney complications checked in a child with LACC1-associated arthritis?
Renal amyloidosis is a theoretical complication of prolonged, poorly controlled inflammation rather than a documented LACC1-specific expectation. The care team may individualize urinalysis, kidney-function testing, or serum amyloid A monitoring according to the child’s inflammatory burden.
How can families support a child’s long-term health and independence?
Regular growth checks, nutrition support, physical and occupational therapy, and attention to sleep and emotional wellbeing can support the child and family. As the child gets older, readiness-based transition planning can gradually teach them to manage medications and appointments.

Get notified when new evidence is published on juvenile arthritis due to defect in LACC1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

    Quartier P, Belot A, Breton S, et al.

    La Revue de medecine interne 2025; (46(8)):449-481 doi:10.1016/j.revmed.2025.06.001.

    PMID: 40544011
  2. 2

    New or vanishing frontiers: LACC1-associated juvenile arthritis.

    Al-Mayouf SM, Yateem M, Al-Dusery H, et al.

    International journal of pediatrics & adolescent medicine 2021; (8(1)):44-47 doi:10.1016/j.ijpam.2020.11.005.

    PMID: 33718577
  3. 3

    Clinical and genetic analysis of Majeed syndrome caused by LPIN2 complex heterozygous mutation and literature review.

    Wang S, Yu T, He X, et al.

    Frontiers in pediatrics 2025; (13()):1602509 doi:10.3389/fped.2025.1602509.

    PMID: 41113563
  4. 4

    Sacroiliitis in familial Mediterranean fever: A rare joint involvement of the disease.

    Özçelik E, Çelikel E, Tekin ZE, et al.

    Journal of paediatrics and child health 2024; (60(10)):511-515 doi:10.1111/jpc.16623.

    PMID: 39051573
  5. 5

    EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update.

    Ozen S, Sağ E, Oton T, et al.

    Annals of the rheumatic diseases 2025; (84(6)):899-909 doi:10.1016/j.ard.2025.01.028.

    PMID: 40234174
  6. 6

    A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity.

    Butbul Aviel Y, Ofir A, Ben-Izhak O, et al.

    Rheumatology (Oxford, England) 2021; (60(10)):4888-4898 doi:10.1093/rheumatology/keab017.

    PMID: 33493343
  7. 7

    Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course.

    Kallinich T, Thorwarth A, von Stuckrad SL, et al.

    Pediatric rheumatology online journal 2016; (14(1)):63 doi:10.1186/s12969-016-0124-2.

    PMID: 27881174
  8. 8

    Nutritional Aspects of Juvenile Idiopathic Arthritis: An A to Z for Dietitians.

    Grammatikopoulou MG, Gkiouras K, Syrmou V, et al.

    Children (Basel, Switzerland) 2023; (10(2)) doi:10.3390/children10020203.

    PMID: 36832332
  9. 9

    Fecal Calprotectin to Detect Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis.

    Ferrara G, Pastore S, Sancin L, et al.

    The Journal of rheumatology 2018; (45(10)):1418-1421 doi:10.3899/jrheum.171200.

    PMID: 29907671
  10. 10

    A child with systemic onset juvenile idiopathic arthritis and nephrotic syndrome.

    Singhal JS, Pande N, Sharma J

    Pediatric nephrology (Berlin, Germany) 2025; (40(2)):381-383 doi:10.1007/s00467-024-06495-2.

    PMID: 39249127
  11. 11

    Proteinuria in children with juvenile idiopathic arthritis: Making the case for early urinary screening.

    Saha A, Pais P, Iyengar AA, Abraham AK

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(6)):1408-1411 doi:10.4103/1319-2442.220854.

    PMID: 29265055
  12. 12

    Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies.

    de Zegher F, Reynaert N, De Somer L, et al.

    Hormone research in paediatrics 2018; (90(5)):337-343 doi:10.1159/000489778.

    PMID: 29940586
  13. 13

    Psychosocial burden in pediatric familial mediterranean fever: A study of quality of life, sleep habits, maternal mental health, and clinical correlates.

    Taşkın SN, Karaca Ahat T, Bozkaya Yücel B, et al.

    BMC psychology 2026; (14(1)).

    PMID: 42773465
  14. 14

    Sleep Quality and Depressive Symptoms in Clinically Stable Pediatric Familial Mediterranean Fever: Associations with Disease Severity and Developmental Factors.

    Baris Cetinkaya B, Battal F

    Children (Basel, Switzerland) 2026; (13(7)) doi:10.3390/children13070950.

    PMID: 42509975
  15. 15

    The cultural differences in transition assessment: Evaluation of TRANSITION-Q and STARx scales on Turkish rheumatic patients.

    Yiğit RE, Çağlayan Ş, Sözeri B

    Archives of rheumatology 2024; (39(2)):255-264 doi:10.46497/ArchRheumatol.2024.10379.

    PMID: 38933719
  16. 16

    Relapses of juvenile idiopathic arthritis in adulthood: A monocentric experience.

    Scagnellato L, Cozzi G, Prosepe I, et al.

    PloS one 2024; (19(5)):e0298679 doi:10.1371/journal.pone.0298679.

    PMID: 38696444

This page is for informational purposes only and does not constitute medical advice. Your child’s care team should tailor monitoring, treatment, and referrals to your child’s individual needs.